about
Serotonin impairment in CSF of PD patients, without an apparent clinical counterpartStrength and weaknesses of cerebrospinal fluid biomarkers in Alzheimer's disease and possible detection of overlaps with frailty process.A clinical and biochemical analysis in the differential diagnosis of idiopathic normal pressure hydrocephalus.Outlining a Population "at Risk" of Parkinson's Disease: Evidence from a Case-Control Study.Abnormal striatal plasticity in a DYT11/SGCE myoclonus dystonia mouse model is reversed by adenosine A2A receptor inhibition.Rotigotine may improve sleep architecture in Parkinson's disease: a double-blind, randomized, placebo-controlled polysomnographic study.Cerebrospinal fluid biomarkers profile of idiopathic normal pressure hydrocephalus.Successful subthalamic stimulation, but levodopa-induced dystonia, in a genetic Parkinson's disease.Subtle alterations of excitatory transmission are linked to presynaptic changes in the hippocampus of PINK1-deficient mice.Early structural and functional plasticity alterations in a susceptibility period of DYT1 dystonia mouse striatum.Heidenhain variant in two patients with inherited V210I Creutzfeldt-Jakob disease.Promising rodent models in Parkinson's disease.Rotigotine may control drooling in patients with Parkinson's Disease: Preliminary findings.Centrality of Early Synaptopathy in Parkinson's Disease.Dietary Vitamin E as a Protective Factor for Parkinson's Disease: Clinical and Experimental EvidenceThe influence of postural deformities on neck function and pain in patients with Parkinson's diseaseLong-term treatment with rotigotine in drug-naïve PSP patientsAssociation between physical activity and dementia's risk factors in patients with Parkinson's disease.Assessment of serum uric acid as risk factor for tauopathiesContinuous dopaminergic stimulation in a patient treated with daytime Levodopa-carbidopa intestinal gel and overnight Rotigotine: a case reportClinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear PalsyDystonia: Are animal models relevant in therapeutics?Loss of Non-Apoptotic Role of Caspase-3 in the PINK1 Mouse Model of Parkinson's DiseaseOccurrence of Writing Tremor in Patients With Scans Without Evidence of Dopaminergic Deficit
P50
Q33921178-22EF5A06-4780-48FB-832B-D7C9B7C5CA74Q38097902-7207FD3B-9BB7-41E8-8F60-01FC0976560FQ39901305-EFCAF270-AB7A-43C4-B113-505F1C9A4B2FQ40406670-C97552EF-D12C-4EFD-BCD9-B38F2F8B0517Q47793274-E6646195-B602-424B-971E-4E4625DBADC3Q47834047-74E700A8-3E36-473E-A815-E8EC1364433EQ48201793-7955D6DA-F8DB-4C58-B805-AEA6CFF7A6AEQ48603445-86374E83-BEEF-4C21-B689-BC3835D1318BQ48924933-727A0851-B14A-42FF-BA23-E46212C74464Q50420863-1CD7B5BA-F508-4976-A84A-4B7481E13F1AQ52925213-F43EB8A9-C090-409F-8E1C-9AA9704B0F00Q53133294-61AB9186-F558-423F-B455-66EA7FBE7D14Q53400984-F1BBBC68-4928-4C1E-85AC-1FFDDC279DF4Q55071517-30A542F7-2DE6-4705-A5D9-B51F094414FFQ64100690-AC87489A-113A-4A06-8603-C8A3A44228CFQ64780322-9E0C4626-2AD2-4B11-B739-024B5A59B945Q64864387-CDBE7917-1499-4820-B234-A604A3B29624Q64974543-51633170-75EC-4AA6-B272-D6ABD84D4137Q88325325-1FAFD67F-B344-4465-9D5B-28F3B582FCF4Q88858403-8EC87979-925F-41E7-960B-58190EEDDE19Q89283722-6E8A5219-354D-412D-BBB7-04B20C534A61Q91182191-7A904CB2-A6A1-41FA-B63A-8F7D164DA43EQ92127436-BAF35576-0C09-4876-ABCE-04988EB74A22Q92583999-910951EA-BF56-4652-A7CF-AB58E97B730A
P50
description
researcher ORCID ID = 0000-0003-3373-5073
@en
wetenschapper
@nl
name
Paola Imbriani
@ast
Paola Imbriani
@en
Paola Imbriani
@es
Paola Imbriani
@nl
type
label
Paola Imbriani
@ast
Paola Imbriani
@en
Paola Imbriani
@es
Paola Imbriani
@nl
prefLabel
Paola Imbriani
@ast
Paola Imbriani
@en
Paola Imbriani
@es
Paola Imbriani
@nl
P106
P1153
36196573500
P21
P31
P496
0000-0003-3373-5073